Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease
Author
dc.contributor.author
Sánchez Valdéz, Fernando J.
Author
dc.contributor.author
Pérez Brandán, Cecilia
Author
dc.contributor.author
Ferreira, Arturo
Author
dc.contributor.author
Basombrío, Miguel Ángel
Admission date
dc.date.accessioned
2019-03-18T11:52:31Z
Available date
dc.date.available
2019-03-18T11:52:31Z
Publication date
dc.date.issued
2014
Cita de ítem
dc.identifier.citation
Expert Rev. Vaccines Early online, 1–17 (2014)
Identifier
dc.identifier.issn
17448395
Identifier
dc.identifier.issn
14760584
Identifier
dc.identifier.other
10.1586/14760584.2015.989989
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/166536
Abstract
dc.description.abstract
Chagas disease is a neglected tropical disease caused by the protozoan parasite Trypanosoma
cruzi. This illness is now becoming global, mainly due to congenital transmission, and so far,
there are no prophylactic or therapeutic vaccines available to either prevent or treat Chagas
disease. Therefore, different approaches aimed at identifying new protective immunogens are
urgently needed. Live vaccines are likely to be more efficient in inducing protection, but
safety issues linked with their use have been raised. The development of improved protozoan
genetic manipulation tools and genomic and biological information has helped to increase
the safety of live vaccines. These advances have generated a renewed interest in the use of
genetically attenuated parasites as vaccines against Chagas disease. This review discusses the
protective capacity of genetically attenuated parasite vaccines and the challenges and
perspectives for the development of an effective whole-parasite Chagas disease vaccine.